959624-43-2

Usage

Molecular Structure

A synthetic molecule with a benzopyran ring and various substituents, including a methyl group, a 4-methyl-1-piperazinyl group, and a phenyl group.

Properties

Antipsychotic and antianxiety

Function

Acts as a serotonin and dopamine receptor antagonist

Uses

Treatment of schizophrenia, bipolar disorder, anxiety disorders, and as an adjunctive therapy for depression

Mechanism of Action

Blocks the transmission of certain neurotransmitters in the brain, leading to its therapeutic effects

Efficacy

Effective in reducing symptoms such as hallucinations, delusions, and emotional disturbances.

Upstream product

• 117635-46-8 1-(tert-butyldimethylsilyloxy)-4-((tert-butyldimethylsilyloxy)methyl)benzene 
• 126070-20-0 4-((tert-butyldimethylsilyloxy)methyl)phenol 
• 623-05-2 (4-hydroxyphenyl)methanol 
• 109-01-3 1-methyl-piperazine 
• 14371-10-9 (E)-3-phenylpropenal 

Downstream Products

• 959624-24-9 (2-hydroxy-4-phenyl-3,4-dihydro-2H-chromen-6-yl)methanol 
• 207679-81-0 (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)-phenol 
• 200801-70-3 RS-N,N-diisopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF 2 -HYDROXY- 4 -PHENYL -3, 4 -DIHYDRO-2H-CHROMEN- 6 -YL -METHANOL AND (R) - FESO - DEACYL

The present invention regards an improved and industrially advantageous process for the preparation of the 2-hyaroxy-4-phenyl-3,4-dihydro-2H-chromen-6-yl-methanol intermediates, also called "feso chromenyl" and (R)-2-[3-(diisopropylamino)-l- phenylpropyl]-4-(hydroxymethyl)phenol, also called "(R)-feso deacyl", which are in turn used in the synthesis of fesoterodine and in particular of fesoterodine furnarate. This process utilises reagents which are non-toxic and manageable at industrial level and enables obtaining a new stable and non-hygroscopic crystalline form of the key intermediate "(R)-feso deacyl", called form B.

PROCESS FOR THE PRODUCTION OF BENZOPYRAN-2-OL DERIVATIVES

The invention provides a process for the production of a compound of formula (I), wherein Y is selected from CH3, CH2OH, CH2CH2OH, CH2Br and Br; comprising the steps of: (i) reacting a compound of formula (II), wherein OX is hydroxy or O- M+, in which M+ is a cation selected from Li+, Na+ and K+, and Y is as defined above; with trans-cinnamaldehyde (III), in the presence of a secondary amine compound; then (ii) treating the product of the preceding step with acid to afford the compound of formula (I). The above process may be used in the production of tolterodine and fesoterodine, which are useful in the treatment of overactive bladder.